JP2013537404A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013537404A5 JP2013537404A5 JP2013516758A JP2013516758A JP2013537404A5 JP 2013537404 A5 JP2013537404 A5 JP 2013537404A5 JP 2013516758 A JP2013516758 A JP 2013516758A JP 2013516758 A JP2013516758 A JP 2013516758A JP 2013537404 A5 JP2013537404 A5 JP 2013537404A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- present
- double
- stranded nucleic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004707 nucleic acids Proteins 0.000 claims 43
- 150000007523 nucleic acids Chemical class 0.000 claims 43
- 102000039446 nucleic acids Human genes 0.000 claims 43
- 125000002652 ribonucleotide group Chemical group 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 15
- 108091028664 Ribonucleotide Proteins 0.000 claims 13
- 108091081021 Sense strand Proteins 0.000 claims 13
- 239000002773 nucleotide Substances 0.000 claims 13
- 125000003729 nucleotide group Chemical group 0.000 claims 13
- 239000002336 ribonucleotide Substances 0.000 claims 13
- 230000000692 anti-sense effect Effects 0.000 claims 12
- 208000035657 Abasia Diseases 0.000 claims 3
- 239000005547 deoxyribonucleotide Substances 0.000 claims 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims 3
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 101150111584 RHOA gene Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35801210P | 2010-06-24 | 2010-06-24 | |
| US61/358,012 | 2010-06-24 | ||
| PCT/US2011/041562 WO2011163436A1 (en) | 2010-06-24 | 2011-06-23 | Double stranded rna compounds to rhoa and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013537404A JP2013537404A (ja) | 2013-10-03 |
| JP2013537404A5 true JP2013537404A5 (enExample) | 2014-07-31 |
| JP5824515B2 JP5824515B2 (ja) | 2015-11-25 |
Family
ID=44453954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013516758A Expired - Fee Related JP5824515B2 (ja) | 2010-06-24 | 2011-06-23 | Ｒｈｏａに対する二本鎖ｒｎａ化合物およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9045755B2 (enExample) |
| EP (1) | EP2585594B1 (enExample) |
| JP (1) | JP5824515B2 (enExample) |
| KR (1) | KR101553753B1 (enExample) |
| CN (1) | CN103097534B (enExample) |
| AU (1) | AU2011270896B9 (enExample) |
| CA (1) | CA2801928C (enExample) |
| IL (1) | IL223578A (enExample) |
| NZ (1) | NZ604094A (enExample) |
| RU (1) | RU2012153703A (enExample) |
| SG (1) | SG186438A1 (enExample) |
| WO (1) | WO2011163436A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2851296C (en) | 2011-11-03 | 2020-08-25 | Quark Pharmaceuticals, Inc. | Methods and compositions for neuroprotection |
| KR101744169B1 (ko) * | 2013-08-12 | 2017-06-09 | 사회복지법인 삼성생명공익재단 | 종양 질환 진단용 바이오마커 및 이의 용도 |
| US10563265B2 (en) | 2013-09-06 | 2020-02-18 | Chugai Seiyaku Kabushiki Kaisha | Use of RHOA in cancer diagnosis and inhibitor screening |
| KR101754478B1 (ko) | 2015-08-06 | 2017-07-07 | 순천향대학교 산학협력단 | 위축성 질염 진단용 바이오 마커 조성물 및 이를 포함하는 진단키트 |
| EP3548005A4 (en) | 2016-11-29 | 2020-06-17 | Puretech Health LLC | Exosomes for delivery of therapeutic agents |
| CN108245528A (zh) * | 2018-02-01 | 2018-07-06 | 河南省立眼科医院（河南省眼科研究所） | 一种视神经保护的药物 |
| CN112315984B (zh) * | 2020-09-09 | 2023-02-14 | 山东省科学院生物研究所 | 海洋来源磷脂在促进血管生成方面的应用 |
| CN113887569B (zh) * | 2021-09-09 | 2022-10-25 | 同济大学 | 一种基于区域尺度的事故多发区域判别方法 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US4959217A (en) | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
| US4925678A (en) | 1987-04-01 | 1990-05-15 | Ranney David F | Endothelial envelopment drug carriers |
| US5080646A (en) | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5270030A (en) | 1988-12-29 | 1993-12-14 | Bio-Technology General Corp. | Fibrin binding domain polypeptide and method of producing |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5167616A (en) | 1989-12-14 | 1992-12-01 | Alza Corporation | Iontophoretic delivery method |
| US6153737A (en) | 1990-01-11 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| US5214136A (en) | 1990-02-20 | 1993-05-25 | Gilead Sciences, Inc. | Anthraquinone-derivatives oligonucleotides |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
| US5225182A (en) | 1991-10-31 | 1993-07-06 | Sharma Yash P | Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system |
| CA2126691C (en) | 1991-12-24 | 2003-05-06 | Phillip Dan Cook | Gapped 2' modified oligonucleotides |
| AU687736B2 (en) | 1992-05-11 | 1998-03-05 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting viral replication |
| CA2140343A1 (en) | 1992-07-17 | 1994-02-03 | Sean M. Sullivan | Method and reagent for treatment of animal diseases |
| US6235886B1 (en) | 1993-09-03 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Methods of synthesis and use |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| DE69433036T2 (de) | 1993-09-03 | 2004-05-27 | Isis Pharmaceuticals, Inc., Carlsbad | Aminoderivatisierte nukleoside und oligonukleoside |
| US5624803A (en) | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
| ATE386131T1 (de) | 1994-04-13 | 2008-03-15 | Univ Rockefeller | Aav-vermittelte überbringung von dna in zellen des nervensystems |
| US6447796B1 (en) | 1994-05-16 | 2002-09-10 | The United States Of America As Represented By The Secretary Of The Army | Sustained release hydrophobic bioactive PLGA microspheres |
| AU4412096A (en) | 1994-12-13 | 1996-07-03 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US6251666B1 (en) | 1997-03-31 | 2001-06-26 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid catalysts comprising L-nucleotide analogs |
| US6235310B1 (en) | 1997-04-04 | 2001-05-22 | Valentis, Inc. | Methods of delivery using cationic lipids and helper lipids |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| JP2003528024A (ja) | 1997-12-16 | 2003-09-24 | バレンティス・インコーポレーテッド | 製剤化された核酸分子の無針注入 |
| CA2317549C (en) | 1998-01-05 | 2006-04-11 | University Of Washington | Composition for enhancing transport through lipid-containing membranes, and uses thereof |
| WO2000003683A2 (en) | 1998-07-20 | 2000-01-27 | Inex Pharmaceuticals Corporation | Liposomal encapsulated nucleic acid-complexes |
| US6410323B1 (en) | 1999-08-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of human Rho family gene expression |
| US5945290A (en) * | 1998-09-18 | 1999-08-31 | Isis Pharmaceuticals, Inc. | Antisense modulation of RhoA expression |
| DE60040274D1 (de) | 1999-03-10 | 2008-10-30 | Phogen Ltd | Verabreichung von nukleinsäuren und proteinen an zellen |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US20040038241A1 (en) | 2000-07-26 | 2004-02-26 | Martin Glennsbjerg | Spatially resolved enzyme-linked assay |
| CZ302719B6 (cs) | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
| US20020130430A1 (en) | 2000-12-29 | 2002-09-19 | Castor Trevor Percival | Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products |
| US20030077829A1 (en) | 2001-04-30 | 2003-04-24 | Protiva Biotherapeutics Inc.. | Lipid-based formulations |
| US20040019001A1 (en) | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
| US6586524B2 (en) | 2001-07-19 | 2003-07-01 | Expression Genetics, Inc. | Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier |
| US7060498B1 (en) | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
| US7141540B2 (en) | 2001-11-30 | 2006-11-28 | Genta Salus Llc | Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
| US20050106731A1 (en) | 2002-08-05 | 2005-05-19 | Davidson Beverly L. | siRNA-mediated gene silencing with viral vectors |
| DE60310944T3 (de) | 2002-08-05 | 2017-08-03 | Silence Therapeutics Gmbh | Weitere neue formen von interferierende rns moleküle |
| EP1633890B2 (en) * | 2003-06-02 | 2020-11-18 | University of Massachusetts | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF FNAi |
| US20050136437A1 (en) | 2003-08-25 | 2005-06-23 | Nastech Pharmaceutical Company Inc. | Nanoparticles for delivery of nucleic acids and stable double-stranded RNA |
| WO2005113770A1 (en) * | 2004-05-13 | 2005-12-01 | Institut Gustave Roussy | Anti-rhoa and -rhoc sirnas and therapeutic compositions comprising them. |
| EP2230305A1 (en) * | 2005-07-21 | 2010-09-22 | Alnylam Pharmaceuticals Inc. | Rnai modulation of the rho-a gene and uses thereof |
| US7825099B2 (en) * | 2006-01-20 | 2010-11-02 | Quark Pharmaceuticals, Inc. | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes |
| WO2007091269A2 (en) | 2006-02-08 | 2007-08-16 | Quark Pharmaceuticals, Inc. | NOVEL TANDEM siRNAS |
| JP2010507387A (ja) * | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| CA2701845A1 (en) | 2007-10-03 | 2009-04-09 | Quark Pharmaceuticals, Inc. | Novel sirna structures |
| WO2009062199A1 (en) | 2007-11-09 | 2009-05-14 | Fox Chase Cancer Center | EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS |
| CN102272307A (zh) * | 2008-11-21 | 2011-12-07 | 利莱恩斯生命科学有限公司 | siNA介导的VEGF-C和RhoA的敲低对VEGF-A分泌、血管生成和/或新血管生成的抑制 |
| WO2011084193A1 (en) | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
-
2011
- 2011-06-23 CN CN201180036371.XA patent/CN103097534B/zh not_active Expired - Fee Related
- 2011-06-23 CA CA2801928A patent/CA2801928C/en not_active Expired - Fee Related
- 2011-06-23 JP JP2013516758A patent/JP5824515B2/ja not_active Expired - Fee Related
- 2011-06-23 NZ NZ604094A patent/NZ604094A/en not_active IP Right Cessation
- 2011-06-23 KR KR1020137001674A patent/KR101553753B1/ko not_active Expired - Fee Related
- 2011-06-23 EP EP11728750.8A patent/EP2585594B1/en not_active Not-in-force
- 2011-06-23 US US13/700,942 patent/US9045755B2/en not_active Expired - Fee Related
- 2011-06-23 SG SG2012094652A patent/SG186438A1/en unknown
- 2011-06-23 WO PCT/US2011/041562 patent/WO2011163436A1/en not_active Ceased
- 2011-06-23 AU AU2011270896A patent/AU2011270896B9/en not_active Ceased
- 2011-06-23 RU RU2012153703/10A patent/RU2012153703A/ru not_active Application Discontinuation
-
2012
- 2012-12-12 IL IL223578A patent/IL223578A/en active IP Right Grant
-
2015
- 2015-12-17 US US14/973,388 patent/US20160102313A1/en not_active Abandoned
-
2016
- 2016-08-04 US US15/228,214 patent/US20160333354A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013537404A5 (enExample) | ||
| JP2014509511A5 (enExample) | ||
| JP2012505657A5 (enExample) | ||
| JP2015511821A5 (enExample) | ||
| Sheng et al. | Structure‐based DNA‐targeting strategies with small molecule ligands for drug discovery | |
| JP2016116520A5 (enExample) | ||
| JP2010166916A5 (enExample) | ||
| JP2017079759A5 (enExample) | ||
| JP2012130342A5 (enExample) | ||
| JP2018530530A5 (enExample) | ||
| JP2020022483A5 (enExample) | ||
| JP2012050438A5 (enExample) | ||
| JP2013510561A5 (enExample) | ||
| JP2016502858A5 (enExample) | ||
| JP2017505623A5 (enExample) | ||
| JP2013511990A5 (enExample) | ||
| HRP20191232T1 (hr) | Inhibicija, posredovana rna interferencijom, ekspresije gena virusa hepatitisa b (hbv) korištenjem kratkih interferirajućih nukleinskih kiselina (sina) | |
| JP2018512041A5 (enExample) | ||
| JP2014515762A (ja) | ペプチドオリゴヌクレオチドコンジュゲート | |
| JP2019511491A5 (enExample) | ||
| JP2017510542A5 (enExample) | ||
| JP2009524696A5 (enExample) | ||
| JP2014518612A5 (enExample) | ||
| JP2019534009A5 (enExample) | ||
| JP2013535212A5 (enExample) |